AI Article Synopsis
- The study aimed to compare the medical impact of measles, influenza, and COVID-19 on children in Bnei Brak, Israel, from 2018 to 2021.
- It recorded hospitalisation numbers and rates for each infection, finding that 247 children were admitted for influenza, 65 for COVID-19, and only 32 for measles.
- Results showed that measles had the highest complication rates, with hospitalisation risks significantly greater for measles and influenza compared to COVID-19.
Article Abstract
Aim: To examine and compare the medical burden of measles, influenza and COVID-19 outbreaks in the city of Bnei Brak, Israel.
Methods: The study was conducted during 2018-2021. The numbers of hospitalisations for these infections and their complications were recorded. Hospitalisation rates were determined by using the number of children residing in Bnei Brak and hospitalised with these infections during the study period as the numerators. The denominators were the estimated paediatric cases of measles, influenza and COVID-19 in Bnei Brak and were calculated under both pragmatic and conservative assumptions.
Results: A total of 247, 65 and 32 children were hospitalised with influenza, COVID-19 and measles respectively. Complication rates were higher following measles than after influenza and SARS-CoV-2 infections. Hospitalisation rates were 10% for measles, 0.6%-1.2% for influenza and 0.15% - 0.25% for COVID-19 infections. Relative risks (RR) with 95% confidence intervals (CI) for hospitalisation following measles compared with COVID-19 ranged from 42 (26.3-67.3) to 70.1 (43.8-112.1), while the relative risks for influenza hospitalisation ranged from 2.5 (1.83-3.41) to 8.2 (6.0-11.2), compared with COVID-19 infection.
Conclusion: Hospitalisation rates and direct medical burdens of measles and influenza were significantly higher than those of COVID-19 infection in children.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/apa.16210 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Scrutinizing the COVID-19 vaccine safety debate.
Hum Vaccin Immunother
December 2024
Preventive Medicine, Second Cluster, Ministry of Health, Riyadh, Saudi Arabia.
The controversy surrounding the safety of coronavirus disease-19 vaccinations is part of a larger historical backdrop of ongoing discussions regarding vaccine safety that have spanned several decades. The historical disputes around measles, mumps, rubella, and influenza highlight the recurring pattern in which public doubt is fueled by false information and personal stories. A 2024 multinational study in the journal presented preexisting safety indicators for myocarditis, pericarditis, Guillain - Barré syndrome, and cerebral venous sinus thrombosis.
View Article and Find Full Text PDFNonhuman primate models of pediatric viral diseases.
Front Cell Infect Microbiol
December 2024
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, United States.
Infectious diseases are the leading cause of death in infants and children under 5 years of age. exposure to viruses can lead to spontaneous abortion, preterm birth, congenital abnormalities or other developmental defects, often resulting in lifelong health sequalae. The underlying biological mechanisms are difficult to study in humans due to ethical concerns and limited sample access.
View Article and Find Full Text PDFTrends in adolescent and adult vaccination in pharmacy and medical settings in the United States, 2018-2024: a database study.
Expert Rev Vaccines
December 2025
Outcomes Research, Merck & Co. Inc ., Rahway, NJ, USA.
Background: Pharmacies can increase access to vaccines. This study aimed to describe trends in the proportion of adolescent and adult vaccinations administered in pharmacies in the United States from 2018 to 2024.
Research Design And Methods: This was a retrospective cross-sectional analysis of medical and pharmacy claims from commercial health insurance enrollees.
Undernutrition and antibody response to measles, tetanus and Haemophilus Influenzae type b (Hib) vaccination in pre-school south African children: The VHEMBE birth cohort study.
Vaccine
December 2024
Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
Background: Under-vaccination is undoubtedly driving recent worldwide measles outbreaks, but undernutrition may also be playing a role in low- and middle-income countries. Studies have shown reduced immune response to vaccines in undernourished children but few have followed children beyond infancy, when they are more likely to be exposed to infectious diseases.
Methods: In the Venda Health Examination of Mothers, Babies and the Environment (VHEMBE) South African birth cohort study, we examined the relationship between undernutrition, as measured by stunting and other growth measures, and vaccine-specific serum antibody level to three different vaccine types: measles, tetanus and Haemophilus influenzae type b (Hib).
Inequalities in uptake of childhood vaccination in England, 2019-23: longitudinal study.
BMJ
December 2024
Department of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, UK.
Objective: To quantify changes in inequalities in uptake of childhood vaccination during a period of steadily declining overall childhood vaccination rates in England.
Design: Longitudinal study.
Setting: General practice data for five vaccines administered to children (first and second doses of the measles, mumps, and rubella vaccine (MMR1 and MMR2, respectively), rotavirus vaccine, pneumococcal conjugate vaccine (PCV) booster, and six-in-one (DTaP/IPV/Hib/HepB) vaccine covering diphtheria, tetanus, pertussis, polio, type b, and hepatitis B) from the Cover of Vaccination Uptake Evaluated Rapidly dataset in England.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!